Bibliographic Details
| Title: |
Efficacy of some selected neo-adjuvant chemotherapy regimens in the treatment of advanced oral squamous cell carcinoma, and their effects on immune function. |
| Authors: |
Yilei Liang1, Fujun Li1, Jiajie Huang1, Zhenni Zhang2 jsbu7t@163.com |
| Source: |
Tropical Journal of Pharmaceutical Research. Nov2021, Vol. 20 Issue 11, p2419-2424. 6p. |
| Subject Terms: |
*PROGRESSION-free survival, *CETUXIMAB, *NEOADJUVANT chemotherapy, *SQUAMOUS cell carcinoma, *ORAL drug administration, *DOCETAXEL, *CISPLATIN |
| Abstract: |
Purpose: To investigate the clinical efficacy of different neo-adjuvant chemotherapy (NACT) regimens in the treatment of advanced oral squamous cell carcinoma (OSCC), and their influence on immune function of the patients. Methods: Advanced OSCC patients (n = 94) who received NACT served as subjects in this study. They were assigned to 2 different treatment groups. Forty patients received docetaxel and fluorouracil regimen (DF group), while 54 patients received taxotere, cisplatin and fluorouracil regimen (TPF group). Surgery was performed after NACT. Changes in clinical efficacy and immune function were monitored in both groups. The clinical baseline data of patients were assessed prior to the treatments. Independent indicators of prognosis were determined using Cox regression analysis (CRA). Results: Clinical treatment efficacy was higher in TPF group than in DF group (p < 0.05). Objective remission rate (ORR) in DF group was lower than that in TPF group (p < 0.05). After chemotherapy, both groups had increased levels of CD4+ and CD4+/CD8+, and reduced level of CD8+, when compared with pre-chemotherapy values, with higher levels of CD4+ and CD4+/CD8+ ratio, and lower level of CD8+ in TPF group than in DF group (p < 0.05). Multivariate CRA revealed that the independent factors for prognosis of oral carcinoma (OC) were tumor node metastasis (TNM) stage and lymph node metastasis. Conclusion: These results indicate that TFP regimen improves clinical efficacy and immune function in patients with advanced OSCC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Tropical Journal of Pharmaceutical Research is the property of Pharmacotherapy Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
